Shavit Capital, a Jerusalem, Israel-based firm specializing in pre-IPO investments, completed a $100m funding for its fifth fund.
Investors include financial institutions from the United States, Asia and Israel, as well as owners and senior managers of investment banks and multibillion dollar hedge funds.
Founded and managed by Gary Leibler, Shavit Capital specializes in pre-IPO investments in technology companies with a special focus on the life science sectors. With the new vehicle, the firm is expected to expand its activities to include companies nearing flotation in other markets, such as Europe, Canada, Australia and Hong Kong.
Shavit, which works closely with most of the leading international investment banks that specialize in raising capital for Israeli companies, leads investment rounds ranging in size from $20 million to $60 million.
The firm has over $400m under management in five funds and its portfolio includes Foamix Pharmaceuticals, Kamada, Anchiano Tx (formerly BioCancell), Gamida Cell, Brainsway, Alpha TAU Medical, and PolyPid.
Beyond Leibler, partners include:
– Leon Recanati, chairman and CEO of the private investment company GlenRock Israel;
– Jonathan Leibler; Gabriel Menaged; and
– Erez Yuval.
Roni Rosenheimer is a Venture Partner.